Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8669721 | 0.74 | KDM4E (0.40) | LMNAHTTMAPTKDM4EPKM | |
| SCHEMBL528130 | 0.74 | LMNA (0.40) | LMNAHTTMAPTKDM4EGOT1 | |
| SCHEMBL7368978 | 0.73 | LMNA (0.61) | LMNAHTTMAPTKDM4EPKM | |
| SCHEMBL3238859 | 0.72 | GPR3 (0.45) | LMNAHTTMAPTKDM4EPKM | |
| SCHEMBL22045624 | 0.71 | GPR3 (0.54) | LMNAHTTKDM4EPKMCYP1A2 | |
| SCHEMBL10446337 | 0.70 | CLK1 (0.32) | — | |
| SCHEMBL7364735 | 0.69 | LMNA (0.40) | LMNAHTTMAPTKDM4EPKM | |
| Ethylamine SCHEMBL11033934 | 0.67 | HTR2A (0.34) | LMNAHTTMAPTKDM4EGOT1 | |
| SCHEMBL3257697 | 0.67 | KDM4E (0.47) | LMNAMAPTKDM4EGPR3SMN1; SMN2 | |
| SCHEMBL18099785 | 0.67 | MAPT (0.70) | LMNAHTTMAPTKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | claimed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | claimed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| WO-2021262731-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-12-30 | — | — | WO | claimed |
| EP-0638560-A1 | REMEDY FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-02-15 | — | — | EP | claimed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2021262731-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2864336-B1 | BENZO[B]ISOXAZOLOAZEPINE BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9085582-B2 | Benzotriazolodiazepine compounds inhibitors of bromodomains | GLAXOSMITHKLINE LLC (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130079335-A1 | Benzotriazolodiazepine Compounds Inhibitors Of Bromodomains | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| US-5753649-A | Therapeutic agent for osteoporosis and diazepine compound | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5593988-A | DIAZIPINE DERIVATIVES OF THIOPHENE FOR BONE DISORDERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0638560-A1 | REMEDY FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | LMNA 276/4885HTT 613/4885MAPT 3722/4885 |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | LMNA 276/4885HTT 613/4885MAPT 3722/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | LMNA 276/4885HTT 613/4885MAPT 3722/4885 |
| US-20130079335-A1 | Benzotriazolodiazepine Compounds Inhibitors Of Bromodomains | BRD4, BRD3, BRD2 | LMNA 1706/4885HTT 1045/4885MAPT 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.